The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation

Patients with recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) often have chemotherapy‐resistant disease, resulting in poor prognosis. The aim of this study was to learn if inhibition of the mammalian target of rapamycin (mTOR) would produce tumor responses.

[1]  C. Peschel,et al.  A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL , 2009, Annals of Hematology.

[2]  K. Stamatopoulos,et al.  Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation , 2008, Journal of internal medicine.

[3]  D. Moore,et al.  Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphoma , 2008, Cancer.

[4]  R. Rosenquist,et al.  Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination , 2008, Leukemia & lymphoma.

[5]  T. Decker.  Is mTOR inhibition a therapeutic option in chronic lymphocytic leukemia? , 2008, Leukemia & lymphoma.

[6]  A. Jack,et al.  B‐cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle , 2007, British journal of haematology.

[7]  T. Shanafelt,et al.  Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch". , 2007, Leukemia research.

[8]  Lisa L. Smith,et al.  Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. , 2006, Blood.

[9]  Shile Huang,et al.  Predicted mechanisms of resistance to mTOR inhibitors , 2006, British Journal of Cancer.

[10]  R. Fonseca,et al.  Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  K. Do,et al.  Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Andreeff,et al.  Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Marc K Hellerstein,et al.  In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. , 2005, The Journal of clinical investigation.

[14]  C. Peschel,et al.  Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: A new therapeutic option , 2005, Leukemia & lymphoma.

[15]  Lisa L. Smith,et al.  Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. , 2004, Blood.

[16]  S. Verstovsek,et al.  Mammalian target of rapamycin inhibition as therapy for hematologic malignancies , 2004, Cancer.

[17]  H. Döhner,et al.  Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. , 2002, The New England journal of medicine.

[18]  J. Byrd,et al.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. , 2002, Blood.

[19]  S. Schichman,et al.  Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data , 2001, Cancer.

[20]  M. Hidalgo,et al.  The rapamycin-sensitive signal transduction pathway as a target for cancer therapy , 2000, Oncogene.

[21]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Grever,et al.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.

[23]  M. Dyer,et al.  Humanized CD52 monoclonal antibody campath‐1H as first‐line treatment in chronic lymphocytic leukaemia , 1996, British journal of haematology.

[24]  J. Gribben.  Salvage therapy for CLL and the role of stem cell transplantation. , 2005, Hematology. American Society of Hematology. Education Program.

[25]  C. Peschel,et al.  Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. , 2003, Blood.